...
首页> 外文期刊>Allergy >Matrix metalloproteinase-9: a novel biomarker for monitoring disease activity in patients with chronic urticaria patients?
【24h】

Matrix metalloproteinase-9: a novel biomarker for monitoring disease activity in patients with chronic urticaria patients?

机译:基质金属蛋白酶9:用于监测慢性荨麻疹患者疾病活动的新型生物标志物?

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Matrix metalloproteinase (MMP)-9, an enzyme that contributes to inflammatory responses and subsequent tissue remodelling, has recently been suggested to be a good biomarker for monitoring disease activity in patients with chronic urticaria (CU). Here, we assessed whether total MMP-9 and/or active MMP-9 plasma levels are increased and correlated to disease activity in patients with CU. METHODS: Total MMP-9 and active MMP-9 plasma levels were determined by ELISA in 70 CU patients and control subjects (patients with psoriasis and healthy controls). CU activity was measured using weekly and daily composite symptom scores (urticaria activity score) calculated from the number of wheals and the intensity of pruritus. RESULTS: Significantly increased levels of total and active MMP-9 were detected in patients with CU as compared to healthy controls. Interestingly, patients with psoriasis also had clearly elevated plasma levels of total and active MMP-9, indicating that MMP-9 plasma levels do not specifically reflect CU activity. Most notably, total and active MMP-9 levels were not correlated with disease activity in CU or psoriasis patients. CONCLUSION: Plasma MMP-9 is not a good CU biomarker and should not be used for assessing the efficacy of treatment in CU patients or their spontaneous changes in disease activity.
机译:背景:基质金属蛋白酶(MMP)-9是一种有助于炎症反应和随后的组织重塑的酶,最近被认为是监测慢性荨麻疹(CU)患者疾病活动的良好生物标志物。在这里,我们评估了CU患者的总MMP-9和/或活性MMP-9血浆水平是否增加并与疾病活动相关。方法:采用ELISA法测定了70名CU患者和对照对象(牛皮癣患者和健康对照者)的总MMP-9和活性MMP-9血浆水平。使用每周和每天的综合症状评分(荨麻疹活动评分)来测量CU活动,该评分由风团数和瘙痒强度计算得出。结果:与健康对照相比,CU患者中检测到的总MMP-9和活性MMP-9含量显着增加。有趣的是,牛皮癣患者的总MMP-9和活动性MMP-9血浆水平也明显升高,这表明MMP-9血浆水平并未特异性反映CU活性。最值得注意的是,CU或牛皮癣患者的总MMP-9和活性MMP-9水平与疾病活动无关。结论:血浆MMP-9并不是良好的CU生物标志物,不应用于评估CU患者的治疗效果或疾病活动的自然变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号